💬In plain words
What the trial is, and whether it could suit you
The objective of our study is to investigate the clinical significance of thromboelastometric values in the development of thrombotic events and survival in patients with glial tumors, to reduce thromboembolic complications and optimize oncological treatment.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Patients undergoing surgical excision or biopsy with a diagnostic impression of glial tumor who provide written informed consent
Exclusion Criteria:
* Patients under 18 years of age.
* Emergency surgery.
* Patients receiving antiplatelet or anticoagulant treatment.
* Patients with known hematologic diseases associated with coagulation abnormalities. Examples include:
* Congenital or acquired platelet function disorders.
* Congenital deficiency of protein C or protein S.
* Deficiency of coagulation factors II, V, VII, X, XII.
* Glanzmann thrombasthenia.
* Hemophilia A, B, or C.
* Idiopathic thrombocytopenic purpura (ITP).
* von Willebrand disease (types I, II, and III).
* Systemic diseases that cause significant coagulation time alterations:
* Prothrombin time \< 60%.
* Activated partial thromboplastin time (aPTT) \> 50 seconds.
* Patients with suspected glial or neuroglial tumor in the context of long-standing epilepsy
💊
What it tests
- Thromboelastometry values: EXTEM CT, MCF, α-angle below the lower limit of normal. Measurement obtained after anesthetic induction. - PT, aPTT, fibrinogen, platelet count. - Thrombin generation. -
Hospital Clínic Barcelona
Barcelona, Spain
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky